US EditionXyloCor Begins EXACT-2 Trial of Catheter-Based XC001 Gene Therapy to Treat of CAD - Cardiac Interventions Today
Summary by Cardiac Interventions Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
XyloCor Begins EXACT-2 Trial of Catheter-Based XC001 Gene Therapy to Treat of CAD - Cardiac Interventions Today
July 25, 2025—XyloCor Therapeutics, a biopharmaceutical company developing therapies for cardiovascular disease, recently announced the first patient has been enrolled in the EXACT-2 trial. The phase 2b, multicenter, randomized, double-blind study is evaluating the company’s catheter-based gene therapy candidate XC001 (encoberminogene rezmadenovec) in patients with coronary artery disease and refractory angina. EXACT-2, which is composed of 100 …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
